Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Has announcements × durvalumab × Clear all

Phase

Status

Active not recruiting 9 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 27 Cisplatin 18 Carboplatin 18 Paclitaxel 16 Pemetrexed 13 Nivolumab 13 Dexamethasone 13 Ipilimumab 12 Gemcitabine 9 Fluorouracil 9 atezolizumab 8 Trastuzumab 8 Cytarabine 8 Cyclophosphamide 8 Docetaxel 7 zanubrutinib 6 daratumumab 6 Rituximab 6 Lenalidomide 6 Daunorubicin 6 nilotinib 5 fludarabine 5 Sunitinib 5 Prednisone 5 Doxorubicin 5 Capecitabine 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 venetoclax 4 trastuzumab deruxtecan 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02125461 2023-10-10

PACIFIC

AstraZeneca

Phase 3 Completed

713 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡